haloperidol has been researched along with Nerve Degeneration in 30 studies
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.
Nerve Degeneration: Loss of functional activity and trophic degeneration of nerve axons and their terminal arborizations following the destruction of their cells of origin or interruption of their continuity with these cells. The pathology is characteristic of neurodegenerative diseases. Often the process of nerve degeneration is studied in research on neuroanatomical localization and correlation of the neurophysiology of neural pathways.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Haloperidol is a typical antipsychotic drug commonly used to treat a broad range of psychiatric disorders related to dysregulations in the neurotransmitter dopamine (DA)." | 1.62 | Haloperidol Interactions with the dop-3 Receptor in Caenorhabditis elegans. ( Aschner, M; Fachinetto, R; Ferrer, B; Krum, BN; Martins, AC; Milne, GL; Queirós, L; Soares, FAA, 2021) |
| " Piglets subjected to hypoxia followed by asphyxic cardiac arrest were treated with saline or two dosing regimens of PPBP after resuscitation." | 1.36 | Sigma receptor ligand 4-phenyl-1-(4-phenylbutyl)-piperidine modulates neuronal nitric oxide synthase/postsynaptic density-95 coupling mechanisms and protects against neonatal ischemic degeneration of striatal neurons. ( Carter, EL; Koehler, RC; Martin, LJ; Torbey, MT; Yang, ZJ, 2010) |
| " In addition the home cage behaviour of mice administered with the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) using an acute dosing regimen was also investigated." | 1.33 | Further validation of LABORAS using various dopaminergic manipulations in mice including MPTP-induced nigro-striatal degeneration. ( Billinton, A; Brown, M; Chapman, H; Quinn, LP; Stean, TO; Upton, N; Vidgeon-Hart, M; Virley, DJ, 2006) |
| "Behaviour was evaluated by catalepsy tests and activity box." | 1.32 | Potentiation of parkinsonian symptoms by depletion of locus coeruleus noradrenaline in 6-hydroxydopamine-induced partial degeneration of substantia nigra in rats. ( Schmidt, WJ; Srinivasan, J, 2003) |
| "An intensification of catalepsy has been observed upon repeated testing in rats with permanent neurodegeneration of substantia nigra." | 1.32 | Intensification of cataleptic response in 6-hydroxydopamine-induced neurodegeneration of substantia nigra is not dependent on the degree of dopamine depletion. ( Schmidt, WJ; Srinivasan, J, 2004) |
| "The possibility that chronic administration of haloperidol could induce cumulative neuronal loss in the substantia nigra pars reticulata and thereby induce the pathological changes which lead to tardive dyskinesia is discussed." | 1.31 | Acute administration of haloperidol induces apoptosis of neurones in the striatum and substantia nigra in the rat. ( Cooper, AC; Cooper, AJ; Griffiths, MR; Mitchell, IJ, 2002) |
| "In the histopathology of Alzheimer's disease (AD) many signs of oxidative reactions can be found building the basis of the oxidative stress hypothesis of AD." | 1.30 | Vitamin E and other antioxidants in neuroprotection. ( Behl, C, 1999) |
| "Pretreatment with chlormethiazole (100 mg/kg i." | 1.29 | Chlormethiazole, dizocilpine and haloperidol prevent the degeneration of serotonergic nerve terminals induced by administration of MDMA ('Ecstasy') to rats. ( Green, AR; Hewitt, KE, 1994) |
| "Treatment with propranolol enhanced open field performance 1 day after 6-OHDA injection but failed to enhance recovery of consummatory behaviour and body weight control." | 1.27 | Catecholamine-blocking drugs injected at sites of amine accumulation reverse catecholamine degeneration associated deficits. ( Smith, GC; Willis, GL, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 15 (50.00) | 18.7374 |
| 1990's | 6 (20.00) | 18.2507 |
| 2000's | 7 (23.33) | 29.6817 |
| 2010's | 1 (3.33) | 24.3611 |
| 2020's | 1 (3.33) | 2.80 |
| Authors | Studies |
|---|---|
| Krum, BN | 1 |
| Martins, AC | 1 |
| Queirós, L | 1 |
| Ferrer, B | 1 |
| Milne, GL | 1 |
| Soares, FAA | 1 |
| Fachinetto, R | 1 |
| Aschner, M | 1 |
| Yang, ZJ | 1 |
| Carter, EL | 1 |
| Torbey, MT | 1 |
| Martin, LJ | 1 |
| Koehler, RC | 1 |
| Srinivasan, J | 2 |
| Schmidt, WJ | 2 |
| Meredith, GE | 1 |
| Switzer, RC | 1 |
| Napier, TC | 1 |
| Quinn, LP | 1 |
| Stean, TO | 1 |
| Chapman, H | 1 |
| Brown, M | 1 |
| Vidgeon-Hart, M | 1 |
| Upton, N | 1 |
| Billinton, A | 1 |
| Virley, DJ | 1 |
| Wuerthele, SM | 1 |
| Moore, KE | 3 |
| Fuxe, K | 1 |
| Ogren, SO | 1 |
| Hall, H | 1 |
| Agnati, LF | 1 |
| Andersson, K | 1 |
| Köhler, C | 1 |
| Schwarcz, R | 1 |
| Lovell, KL | 1 |
| Bruner, CA | 1 |
| Kondo, Y | 1 |
| Iwatsubo, K | 1 |
| Hewitt, KE | 1 |
| Green, AR | 1 |
| Lipska, BK | 1 |
| Chrapusta, SJ | 1 |
| Egan, MF | 1 |
| Weinberger, DR | 1 |
| Andreassen, OA | 1 |
| Ferrante, RJ | 1 |
| Beal, MF | 1 |
| Jørgensen, HA | 1 |
| Ikonomidou, C | 1 |
| Bosch, F | 1 |
| Miksa, M | 1 |
| Bittigau, P | 1 |
| Vöckler, J | 1 |
| Dikranian, K | 1 |
| Tenkova, TI | 1 |
| Stefovska, V | 1 |
| Turski, L | 1 |
| Olney, JW | 1 |
| Behl, C | 1 |
| Meshul, CK | 1 |
| Allen, C | 1 |
| Mitchell, IJ | 1 |
| Cooper, AC | 1 |
| Griffiths, MR | 1 |
| Cooper, AJ | 1 |
| Marchese, G | 1 |
| Casu, MA | 1 |
| Bartholini, F | 1 |
| Ruiu, S | 1 |
| Saba, P | 1 |
| Gessa, GL | 1 |
| Pani, L | 1 |
| Lucchelli, A | 1 |
| Guidotti, A | 1 |
| Costa, E | 1 |
| Thornburg, JE | 1 |
| Bakker, MH | 1 |
| Foster, AC | 1 |
| Lee, S | 1 |
| Merriam, A | 1 |
| Kim, TS | 1 |
| Liebling, M | 1 |
| Dickson, DW | 1 |
| Moore, GR | 1 |
| Hovda, DA | 1 |
| Sutton, RL | 1 |
| Feeney, DM | 1 |
| Warenycia, MW | 1 |
| McKenzie, GM | 1 |
| Murphy, M | 1 |
| Szerb, JC | 1 |
| Willis, GL | 1 |
| Smith, GC | 1 |
| Woodruff, GN | 1 |
| Elkhawad, AO | 1 |
| Crossman, AR | 1 |
| Ungerstedt, U | 1 |
| Pieri, L | 1 |
| Pieri, M | 1 |
| Haefely, W | 1 |
| Fibiger, HC | 1 |
| Phillips, AG | 1 |
| Bedard, P | 1 |
| Larochelle, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effect of Dexmedetomidine as an Adjuvant to General Anesthesia on Intelligence Development in Pediatric Patients Undergoing Craniotomy: a Randomized, Double-blind and Placebo-controlled Pilot Trial[NCT02810899] | Phase 4 | 60 participants (Actual) | Interventional | 2015-09-30 | Completed | ||
| Anesthesia Exposure and Neurodevelopment in Infants and Children: Pediatric Anesthesia & NeuroDevelopment (PANDA) Study[NCT00881764] | 369 participants (Actual) | Observational | 2009-05-31 | Completed | |||
| Influence of General Anesthesia on the Dynamic Changes in Brain Damage Markers During and After Craniosynostosis Operations in Infancy[NCT05911139] | 45 participants (Anticipated) | Observational [Patient Registry] | 2022-10-01 | Enrolling by invitation | |||
| Effects of General Anesthesia on Brain Functional Connectivity and Cognition in Children With Potential Neurological Damage[NCT05602311] | 120 participants (Anticipated) | Observational [Patient Registry] | 2022-08-15 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for haloperidol and Nerve Degeneration
| Article | Year |
|---|---|
Cerebellar degeneration in neuroleptic malignant syndrome: neuropathologic findings and review of the literature concerning heat-related nervous system injury.
Topics: Adult; Cerebellar Diseases; Cerebellum; Chronic Disease; Dose-Response Relationship, Drug; Fever; Ha | 1989 |
29 other studies available for haloperidol and Nerve Degeneration
| Article | Year |
|---|---|
Haloperidol Interactions with the dop-3 Receptor in Caenorhabditis elegans.
Topics: Animals; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Dopamine; Dopaminergic Neurons; Ge | 2021 |
Sigma receptor ligand 4-phenyl-1-(4-phenylbutyl)-piperidine modulates neuronal nitric oxide synthase/postsynaptic density-95 coupling mechanisms and protects against neonatal ischemic degeneration of striatal neurons.
Topics: Analysis of Variance; Animals; Animals, Newborn; Brain Ischemia; Corpus Striatum; Disease Models, An | 2010 |
Potentiation of parkinsonian symptoms by depletion of locus coeruleus noradrenaline in 6-hydroxydopamine-induced partial degeneration of substantia nigra in rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Behavior, Animal; Benzylamines; Cataleps | 2003 |
Short-term, D2 receptor blockade induces synaptic degeneration, reduces levels of tyrosine hydroxylase and brain-derived neurotrophic factor, and enhances D2-mediated firing in the ventral pallidum.
Topics: Animals; Antipsychotic Agents; Brain-Derived Neurotrophic Factor; Cell Survival; Disease Models, Ani | 2004 |
Intensification of cataleptic response in 6-hydroxydopamine-induced neurodegeneration of substantia nigra is not dependent on the degree of dopamine depletion.
Topics: Analysis of Variance; Animals; Behavior, Animal; Brain Chemistry; Catalepsy; Dopamine; Dopamine Anta | 2004 |
Further validation of LABORAS using various dopaminergic manipulations in mice including MPTP-induced nigro-striatal degeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amphetamine; Animals; Apomorphine; Automation; Behavio | 2006 |
Effect of systemic and intrastriatal injections of haloperidol on striatal dopamine and DOPAC concentrations in rats pretreated by section of nigrostriatal fibres.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Dopamine; Feedback; Glutamate Decarboxylas | 1980 |
Effects of chronic treatment with l-sulpiride and haloperidol on central monoaminergic mechanisms.
Topics: 5-Hydroxytryptophan; Animals; Apomorphine; Behavior, Animal; Biogenic Amines; Brain; Haloperidol; Hy | 1980 |
Lack of effect of cerebellectomy on ascending dopaminergic neurons in the rat brain.
Topics: Animals; Cerebellum; Corpus Striatum; Dominance, Cerebral; Dopamine; Haloperidol; Male; Muridae; Ner | 1982 |
Diminished responses of nigral dopaminergic neurons to haloperidol and morphine following lesions in the striatum.
Topics: Animals; Corpus Striatum; Dopamine; Evoked Potentials; Haloperidol; Kainic Acid; Male; Morphine; Ner | 1980 |
Chlormethiazole, dizocilpine and haloperidol prevent the degeneration of serotonergic nerve terminals induced by administration of MDMA ('Ecstasy') to rats.
Topics: Animals; Chlormethiazole; Dizocilpine Maleate; Haloperidol; Hydroxyindoleacetic Acid; Male; N-Methyl | 1994 |
Neonatal excitotoxic ventral hippocampal damage alters dopamine response to mild repeated stress and to chronic haloperidol.
Topics: Animals; Corpus Striatum; Dopamine; Female; Frontal Lobe; Haloperidol; Handling, Psychological; Hipp | 1995 |
Oral Dyskinesias and striatal lesions in rats after long-term co-treatment with haloperidol and 3-nitropropionic acid.
Topics: Analysis of Variance; Animals; Anti-Dyskinesia Agents; Antihypertensive Agents; Behavior, Animal; Co | 1998 |
Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain.
Topics: Animals; Apoptosis; Brain; Calcium Channel Blockers; Dizocilpine Maleate; Dopamine Antagonists; Dose | 1999 |
Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain.
Topics: Animals; Apoptosis; Brain; Calcium Channel Blockers; Dizocilpine Maleate; Dopamine Antagonists; Dose | 1999 |
Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain.
Topics: Animals; Apoptosis; Brain; Calcium Channel Blockers; Dizocilpine Maleate; Dopamine Antagonists; Dose | 1999 |
Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain.
Topics: Animals; Apoptosis; Brain; Calcium Channel Blockers; Dizocilpine Maleate; Dopamine Antagonists; Dose | 1999 |
Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain.
Topics: Animals; Apoptosis; Brain; Calcium Channel Blockers; Dizocilpine Maleate; Dopamine Antagonists; Dose | 1999 |
Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain.
Topics: Animals; Apoptosis; Brain; Calcium Channel Blockers; Dizocilpine Maleate; Dopamine Antagonists; Dose | 1999 |
Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain.
Topics: Animals; Apoptosis; Brain; Calcium Channel Blockers; Dizocilpine Maleate; Dopamine Antagonists; Dose | 1999 |
Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain.
Topics: Animals; Apoptosis; Brain; Calcium Channel Blockers; Dizocilpine Maleate; Dopamine Antagonists; Dose | 1999 |
Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain.
Topics: Animals; Apoptosis; Brain; Calcium Channel Blockers; Dizocilpine Maleate; Dopamine Antagonists; Dose | 1999 |
Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain.
Topics: Animals; Apoptosis; Brain; Calcium Channel Blockers; Dizocilpine Maleate; Dopamine Antagonists; Dose | 1999 |
Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain.
Topics: Animals; Apoptosis; Brain; Calcium Channel Blockers; Dizocilpine Maleate; Dopamine Antagonists; Dose | 1999 |
Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain.
Topics: Animals; Apoptosis; Brain; Calcium Channel Blockers; Dizocilpine Maleate; Dopamine Antagonists; Dose | 1999 |
Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain.
Topics: Animals; Apoptosis; Brain; Calcium Channel Blockers; Dizocilpine Maleate; Dopamine Antagonists; Dose | 1999 |
Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain.
Topics: Animals; Apoptosis; Brain; Calcium Channel Blockers; Dizocilpine Maleate; Dopamine Antagonists; Dose | 1999 |
Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain.
Topics: Animals; Apoptosis; Brain; Calcium Channel Blockers; Dizocilpine Maleate; Dopamine Antagonists; Dose | 1999 |
Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain.
Topics: Animals; Apoptosis; Brain; Calcium Channel Blockers; Dizocilpine Maleate; Dopamine Antagonists; Dose | 1999 |
Vitamin E and other antioxidants in neuroprotection.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Antipsychotic Agents; Estrogens; Female; Fre | 1999 |
Haloperidol reverses the changes in striatal glutamatergic immunolabeling following a 6-OHDA lesion.
Topics: Animals; Apomorphine; Denervation; Dopamine Agonists; Dopamine Antagonists; Glutamic Acid; Haloperid | 2000 |
Acute administration of haloperidol induces apoptosis of neurones in the striatum and substantia nigra in the rat.
Topics: Animals; Antigens, CD; Antigens, Neoplasm; Antigens, Surface; Apoptosis; Avian Proteins; Basigin; Be | 2002 |
Sub-chronic treatment with classical but not atypical antipsychotics produces morphological changes in rat nigro-striatal dopaminergic neurons directly related to "early onset" vacuous chewing.
Topics: Amisulpride; Animals; Antipsychotic Agents; Clozapine; Dopamine; Dose-Response Relationship, Drug; D | 2002 |
Stratial content of Ca2+-dependent regulator protein and dopaminergic receptor function.
Topics: 2',3'-Cyclic-Nucleotide Phosphodiesterases; Animals; Apomorphine; Calcium; Cerebellum; Corpus Striat | 1978 |
Drug-induced dopaminergic supersensitivity.
Topics: Animals; Apomorphine; Depression, Chemical; Dopamine; Drug Interactions; Haloperidol; Hydroxydopamin | 1975 |
An investigation of the mechanisms of delayed neurodegeneration caused by direct injection of quinolinate into the rat striatum in vivo.
Topics: Adrenergic alpha-Antagonists; Animals; Anticonvulsants; Convulsants; Corpus Striatum; Dialysis; Diaz | 1991 |
Amphetamine-induced recovery of visual cliff performance after bilateral visual cortex ablation in cats: measurements of depth perception thresholds.
Topics: Amphetamine; Animals; Cats; Depth Perception; Discrimination Learning; Dominance, Cerebral; Female; | 1989 |
The effects of cortical ablation on multiple unit activity in the striatum following dexamphetamine.
Topics: Animals; Behavior, Animal; Cerebral Cortex; Corpus Striatum; Dextroamphetamine; Electrophysiology; E | 1987 |
Catecholamine-blocking drugs injected at sites of amine accumulation reverse catecholamine degeneration associated deficits.
Topics: Animals; Behavior, Animal; Dopamine; Dopamine Antagonists; Drinking; Eating; Haloperidol; Hydroxydop | 1985 |
Further evidence for the stimulation of rat brain dopamine receptors by ergometrine.
Topics: Amphetamine; Animals; Brain Chemistry; Corpus Striatum; Dopamine; Ergonovine; Functional Laterality; | 1974 |
Striatal dopamine release after amphetamine or nerve degeneration revealed by rotational behaviour.
Topics: Amphetamine; Animals; Apomorphine; Brain; Butyrophenones; Dopamine; Electrocoagulation; Haloperidol; | 1971 |
LSD as an agonist of dopamine receptors in the striatum.
Topics: Animals; Behavior, Animal; Corpus Striatum; Diencephalon; Dopamine; Dose-Response Relationship, Drug | 1974 |
Role of dopamine and norepinephrine in the chemistry of reward.
Topics: Amphetamine; Animals; Brain; Dopamine; Dose-Response Relationship, Drug; Electrodes, Implanted; Halo | 1974 |
Effect of section of the strionigral fibers on dopamine turnover in the forebrain of the rat.
Topics: Animals; Arecoline; Brain; Corpus Striatum; Dopamine; Feedback; Haloperidol; Homovanillic Acid; Male | 1973 |